Lv1
50 积分 2022-10-07 加入
Current status and future trends of the global burden of MASLD
15天前
已完结
GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
24天前
已完结
Non-invasive tests of fibrosis in the management of MASLD: revolutionising diagnosis, progression and regression monitoring
1个月前
已完结
Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts
1个月前
已完结
Cardiovascular–kidney–metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD
1个月前
已完结
Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
1个月前
已完结
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature
1个月前
已完结
Activated hepatic stellate cells maintain liver bile acid homeostasis through paracrine FGF10/FGFR2 signaling
1个月前
已完结
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD
1个月前
已完结
Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
1个月前
已完结
皖公网安备34019202002308
